BioReliance (Merck) vs Genezen: CDMO Comparison
How does BioReliance (Merck) compare to Genezen for AAV manufacturing?
Side-by-side comparison of BioReliance (Merck) and Genezen on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- BioReliance (Merck) has more FDA inspections on record (6 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- BioReliance (Merck) maintains 10 MHRA / UK GMP certificates; Genezen does not.
On a 13-modality CDMO landscape, both BioReliance (Merck) and Genezen qualify as AAV manufacturers; BioReliance (Merck) carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both BioReliance (Merck) and Genezen qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: BioReliance (Merck) vs Genezen
How does BioReliance (Merck) compare to Genezen for AAV manufacturing?
On CDMO Signal's composite Signal Score, BioReliance (Merck) is 80/100 and Genezen is 78/100; BioReliance (Merck) has 6 FDA inspections on record vs 1 for Genezen; European coverage is 10 active EMA+MHRA certificates for BioReliance (Merck) vs 0 for Genezen. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BioReliance (Merck) or Genezen?
Both BioReliance (Merck) and Genezen maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioReliance (Merck) has 6 FDA inspections on record; Genezen has 1.
How do BioReliance (Merck) and Genezen compare on European GMP coverage?
BioReliance (Merck) holds 0 active EMA GMP certificates and 10 MHRA / UK certificates. Genezen holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — BioReliance (Merck) or Genezen?
Both BioReliance (Merck) and Genezen are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BioReliance (Merck) carries a Signal Score of 80/100 and Genezen carries 78/100 — essentially tied for BioReliance (Merck). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →